X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ALKEM LABORATORIES - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ALKEM LABORATORIES CADILA HEALTHCARE/
ALKEM LABORATORIES
 
P/E (TTM) x 23.5 - - View Chart
P/BV x 5.9 6.7 88.3% View Chart
Dividend Yield % 0.8 0.6 122.9%  

Financials

 CADILA HEALTHCARE   ALKEM LABORATORIES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
ALKEM LABORATORIES
Mar-16
CADILA HEALTHCARE/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs4601,589 28.9%   
Low Rs3051,232 24.8%   
Sales per share (Unadj.) Rs92.1417.5 22.1%  
Earnings per share (Unadj.) Rs14.856.3 26.3%  
Cash flow per share (Unadj.) Rs18.564.7 28.6%  
Dividends per share (Unadj.) Rs3.2012.70 25.2%  
Dividend yield (eoy) %0.80.9 92.9%  
Book value per share (Unadj.) Rs68.0292.9 23.2%  
Shares outstanding (eoy) m1,023.74119.57 856.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.23.4 122.9%   
Avg P/E ratio x25.825.1 103.0%  
P/CF ratio (eoy) x20.721.8 95.0%  
Price / Book Value ratio x5.64.8 116.8%  
Dividend payout %21.622.6 95.7%   
Avg Mkt Cap Rs m391,581168,653 232.2%   
No. of employees `00016.9NA-   
Total wages/salary Rs m15,0029,171 163.6%   
Avg. sales/employee Rs Th5,594.5NM-  
Avg. wages/employee Rs Th890.1NM-  
Avg. net profit/employee Rs Th899.9NM-  
INCOME DATA
Net Sales Rs m94,29549,915 188.9%  
Other income Rs m1,2861,645 78.2%   
Total revenues Rs m95,58151,561 185.4%   
Gross profit Rs m19,0368,482 224.4%  
Depreciation Rs m3,7501,006 372.8%   
Interest Rs m450671 67.1%   
Profit before tax Rs m16,1228,451 190.8%   
Minority Interest Rs m338-114 -297.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,2891,606 80.3%   
Profit after tax Rs m15,1686,731 225.3%  
Gross profit margin %20.217.0 118.8%  
Effective tax rate %8.019.0 42.1%   
Net profit margin %16.113.5 119.3%  
BALANCE SHEET DATA
Current assets Rs m60,22327,062 222.5%   
Current liabilities Rs m53,05815,324 346.3%   
Net working cap to sales %7.623.5 32.3%  
Current ratio x1.11.8 64.3%  
Inventory Days Days7067 105.0%  
Debtors Days Days8841 213.6%  
Net fixed assets Rs m72,98412,610 578.8%   
Share capital Rs m1,024239 428.3%   
"Free" reserves Rs m68,57634,490 198.8%   
Net worth Rs m69,60035,027 198.7%   
Long term debt Rs m24,6841,212 2,037.3%   
Total assets Rs m152,20754,387 279.9%  
Interest coverage x36.813.6 270.7%   
Debt to equity ratio x0.40 1,025.3%  
Sales to assets ratio x0.60.9 67.5%   
Return on assets %10.313.6 75.4%  
Return on equity %21.819.2 113.4%  
Return on capital %17.924.9 72.1%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m21,2806,563 324.2%   
Fx outflow Rs m10,8743,012 361.1%   
Net fx Rs m10,4063,552 293.0%   
CASH FLOW
From Operations Rs m13,4957,259 185.9%  
From Investments Rs m-29,1031,864 -1,561.2%  
From Financial Activity Rs m23,158-9,273 -249.7%  
Net Cashflow Rs m7,556-150 -5,037.3%  

Share Holding

Indian Promoters % 74.8 66.9 111.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 33.1 25.1%  
FIIs % 5.9 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 0.0 -  
Shareholders   44,069 68,381 64.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   STERLING BIOTECH  SANOFI INDIA  DR. DATSONS LABS  ORCHID PHARMA LTD  NOVARTIS  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jun 18, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS